Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Yonghong Liu
Institutions:
The University of Texas MD Anderson Cancer Center,
Baylor College of Medicine,
Guangxi University of Chinese Medicine,
Texas A&M University
Observed institutions:
The University of Texas MD Anderson Cancer Center,
Baylor College of Medicine,
Guangxi University of Chinese Medicine,
Texas A&M University
ORCID:
0000-0003-2609-7720
Observed ORCID:
0000-0003-2609-7720
OpenAlex ID:
A5102859491
Works
16
Awards
1
Combined KRAS Inhibition and Immune Therapy Generates Durable Complete Responses in an Autochthonous PDAC Model
2024
·
Yonghong Liu
, Jincheng Han
, et al.
·
Cancer Discovery
·
47
PDF
Cell lineage tracing links ERα loss in Erbb2-positive breast cancers to the arising of a highly aggressive breast cancer subtype
2021
·
Yunfeng Ding
, Yonghong Liu
, et al.
·
Proceedings of the National Academy of Sciences
·
11
Death receptor 3: A paradoxical biomarker and therapeutic target in pan-cancer
2026
·
Wenxuan Fang
, Junfang Du
, et al.
·
Critical Reviews in Oncology/Hematology
·
3
Data from Combined KRAS Inhibition and Immune Therapy Generates Durable Complete Responses in an Autochthonous PDAC Model
2025
·
Yonghong Liu
, Jincheng Han
, et al.
·
1
Loss of NCOA6 protein causes aggressive prostate cancer with EGFR overexpression and dependency
2026
·
Yonghong Liu
, Zhangwei Tong
, et al.
·
Nature Communications
Table S1 from Combined KRAS Inhibition and Immune Therapy Generates Durable Complete Responses in an Autochthonous PDAC Model
2025
·
Yonghong Liu
, Jincheng Han
, et al.
Figure S5 from Combined KRAS Inhibition and Immune Therapy Generates Durable Complete Responses in an Autochthonous PDAC Model
2025
·
Yonghong Liu
, Jincheng Han
, et al.
PDF
Table S2 from Combined KRAS Inhibition and Immune Therapy Generates Durable Complete Responses in an Autochthonous PDAC Model
2025
·
Yonghong Liu
, Jincheng Han
, et al.
Figure S4 from Combined KRAS Inhibition and Immune Therapy Generates Durable Complete Responses in an Autochthonous PDAC Model
2025
·
Yonghong Liu
, Jincheng Han
, et al.
PDF
Figure S1 from Combined KRAS Inhibition and Immune Therapy Generates Durable Complete Responses in an Autochthonous PDAC Model
2025
·
Yonghong Liu
, Jincheng Han
, et al.
PDF
Figure S3 from Combined KRAS Inhibition and Immune Therapy Generates Durable Complete Responses in an Autochthonous PDAC Model
2025
·
Yonghong Liu
, Jincheng Han
, et al.
PDF
Table S5 from Combined KRAS Inhibition and Immune Therapy Generates Durable Complete Responses in an Autochthonous PDAC Model
2025
·
Yonghong Liu
, Jincheng Han
, et al.
Figure S6 from Combined KRAS Inhibition and Immune Therapy Generates Durable Complete Responses in an Autochthonous PDAC Model
2025
·
Yonghong Liu
, Jincheng Han
, et al.
PDF
Figure S2 from Combined KRAS Inhibition and Immune Therapy Generates Durable Complete Responses in an Autochthonous PDAC Model
2025
·
Yonghong Liu
, Jincheng Han
, et al.
Table S4 from Combined KRAS Inhibition and Immune Therapy Generates Durable Complete Responses in an Autochthonous PDAC Model
2025
·
Yonghong Liu
, Jincheng Han
, et al.
Table S3 from Combined KRAS Inhibition and Immune Therapy Generates Durable Complete Responses in an Autochthonous PDAC Model
2025
·
Yonghong Liu
, Jincheng Han
, et al.
Show more works
View as search
Works count:
16
Citation count:
62
H-index:
3
I10-index:
2
Year
Topic
Type